Your session is about to expire
← Back to Search
Pediatric Participants 8+ Years for Neurofibromatosis
N/A
Waitlist Available
Led By Staci M Peron, Ph.D.
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two cycles
Awards & highlights
Study Summary
This trial will study how often people with neurofibromatosis type 1 take medicine that has been prescribed to them for treating plexiform neurofibromas.
Eligible Conditions
- Neurofibromatosis
- Plexiform Neurofibroma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ cycles 1-4, 5-8, 9-12 and 13-18
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cycles 1-4, 5-8, 9-12 and 13-18
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility
Secondary outcome measures
Patient Characteristics
Pattern
Trial Design
2Treatment groups
Experimental Treatment
Group I: Pediatric Participants 8+ YearsExperimental Treatment1 Intervention
Questionnaires and use of the medication event monitoring system (MEMS^TM)
Group II: Adult ParticipantsExperimental Treatment2 Interventions
Questionnaires and use of the medication event monitoring system (MEMS^TM)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Medication Event Monitoring System (MEMS^TM)
2018
N/A
~20
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
13,667 Previous Clinical Trials
40,926,154 Total Patients Enrolled
3 Trials studying Neurofibromatosis
284 Patients Enrolled for Neurofibromatosis
Staci M Peron, Ph.D.Principal InvestigatorNational Cancer Institute (NCI)
7 Previous Clinical Trials
489 Total Patients Enrolled
2 Trials studying Neurofibromatosis
274 Patients Enrolled for Neurofibromatosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Even though you may have someone helping you take your medication, the way you take your medication may be very different from other people with NF1.There are no specific requirements or restrictions for participation in this study.
Research Study Groups:
This trial has the following groups:- Group 1: Pediatric Participants 8+ Years
- Group 2: Adult Participants
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there any availability for prospective patients to join this research?
"According to information from clinicaltrials.gov, this particular medical experiment is no longer recruiting participants. Despite the trial being initially posted on October 23rd 2018 and last updated November 24th 2022, 56 other trials are actively seeking candidates for their studies."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger